Small cell lung cancer: Time to revisit DNA-damaging chemotherapy

Anish Thomas; Yves Pommier

doi:10.1126/scitranslmed.aaf6282

Small cell lung cancer: Time to revisit DNA-damaging chemotherapy

Sci Transl Med. 2016 Jul 6;8(346):346fs12. doi: 10.1126/scitranslmed.aaf6282.

Authors

Anish Thomas¹, Yves Pommier²

Affiliations

¹ Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. [email protected] [email protected].
² Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. [email protected] [email protected].

Abstract

Rational use of DNA-damaging chemotherapy, with new combinations to heighten DNA replication stress, could improve outcomes in small cell lung cancer.

Publication types

Review
Research Support, N.I.H., Intramural

MeSH terms

Animals
DNA Damage / drug effects
DNA Damage / genetics*
DNA Replication / drug effects
DNA Replication / genetics
Drug Therapy*
Drug-Related Side Effects and Adverse Reactions
Genomic Instability / drug effects
Genomic Instability / genetics
Humans
Lung Neoplasms / genetics*
Small Cell Lung Carcinoma / genetics*

Grants and funding

Z01 BC006150/ImNIH/Intramural NIH HHS/United States